02566nas a2200385   4500000000100000008004100001260004400042653002200086653002000108653002300128653001700151653001500168653003000183653002500213653001800238100002600256700001600282700002400298700001600322700002000338700001300358700001400371700001400385700001700399700001200416700001300428700001400441700002100455245013300476856007300609300000900682490000700691520146800698022001402166       2024                            d  bSpringer Science and Business Media LLC10aTrypanosoma cruzi10aChagas' disease10aTreatment response10aMetabolomics10alipidomics10aPhosphatidylethanolamines10aHydroxydecanoic acid10aSphingolipids1 aGabaldón-Figueira JC1 aRos-Lucas A1 aMartínez-Peinado N1 aBlackburn G1 aLosada-Galvan I1 aPosada E1 aBallart C1 aEscabia E1 aCapellades J1 aYanes O1 aPinazo M1 aGascón J1 aAlonso-Padilla J00aChanges in lipid abundance are associated with disease progression and treatment response in chronic Trypanosoma cruzi infection  uhttps://link.springer.com/content/pdf/10.1186/s13071-024-06548-3.pdf  a1-140 v173 a<p><strong>Background:</strong> Chagas disease, caused by the parasite Trypanosoma cruzi, is a zoonosis that affects more than seven million people. Current limitations on the diagnosis of the disease hinder the prognosis of patients and the evaluation of treatment efficacy, slowing the development of new therapeutic options. The infection is known to disrupt several host metabolic pathways, providing an opportunity for the identification of biomarkers.</p>

<p><strong>Methods:</strong> The metabolomic and lipidomic profiles of a cohort of symptomatic and asymptomatic patients with T. cruzi infection and a group of uninfected controls were analysed using liquid chromatography/mass spectrometry. Differences among all groups and changes before and after receiving anti-parasitic treatment across those with T. cruzi infection were explored.</p>

<p><strong>Results: </strong>Three lipids were found to differentiate between symptomatic and asymptomatic participants: 10-hydroxydecanoic acid and phosphatidylethanolamines PE(18:0/20:4) and PE(18:1/20:4). Additionally, sphinganine, 4-hydroxysphinganine, hexadecasphinganine, and other sphingolipids showed post-treatment abundance similar to that in non-infected controls.</p>

<p><strong>Conclusions: </strong>These molecules hold promise as potentially useful biomarkers for monitoring disease progression and treatment response in patients with chronic T. cruzi infection. Graphical Abstract</p>
  a1756-3305